Sunday, 25. February 2024 Share: YouTube RSS

AbbVie lowers first-quarter guidance after closing acquisition ImmunoGen

AbbVie Inc.’s stock fell 0.5% early Monday, after the biotech lowered its first-quarter guidance to reflect the dilutive impact of its closure of the acquisition of ImmunoGen.

Source: MarketWatch

Continue reading...

Related Articles

×